Novavax, Inc. (NASDAQ:NVAX)

CAPS Rating: 1 out of 5

A biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon current preventive options for a range of infectious diseases.

Recs

0
Player Avatar T5enterprise (74.39) Submitted: 9/1/2009 4:40:15 PM : Outperform Start Price: $6.15 NVAX Score: -112.39

H1N1

Featured Broker Partners


Advertisement